首页>投融资

ImmunOs Therapeutics

C轮

ImmunOs Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel human immunomodulatory proteins and their combination with other cancer therapies such as chemotherapy or vaccines.In April 2021, ImmunOs Therapeutics had partnered with ProteoGenix.In June 2022, ImmunOs Therapeutics AG closed an oversubscribed Series B financing round totalling $74 million led by Samsara BioCapital, Lightspeed Venture Partners and Gimv.In December 2019, the company closed Series A financing of CHF 15 million (US $15.16 million).In April 2021, ImmunOs Therapeutics AG had announced that is had received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse

http://www.immunostherapeutics.com/

470180

基本信息

公司全称

ImmunOs Therapeutics AG
类型

人类免疫调节蛋白研发商
产业领域

药品研发/制造、研发制造服务
公司人数

不明确
地址

Wagistrasse 14 SCHLIEREN ZUERICH 8952; CH;
联系电话
邮箱

info@immunostherapeutics.com
成立时间

2014-01-01

投融资

2024-09-18

C轮

1100万美元

Gimv

辉瑞

Mission BioCapital

BioMedPartners

Double Point Ventures
2022-06-07

B轮

7400万美元

Pfizer Ventures

Gimv

Samsara BioCapital

BioMedPartners

德福资本

Fiscus Financial

Lightspeed Venture Partners

Schroder Adveq

PEAK6

Mission BioCapital
2022-06-07

B轮

7400万美元

Gimv

Lightspeed Venture Partners

Samsara BioCapital

Schroder Adveq

BioMedPartners

辉瑞

Fiscus Financial

PEAK6

德福资本

Mission BioCapital
2019-12-10

A轮

1500万瑞士法郎

Pfizer Ventures

BioMedPartners

Schroder Adveq

Redalpine Venture Partners

Wille Finance
2019-12-10

A轮

1500万瑞士法郎

辉瑞

BioMedPartners

Wille Finance

Schroder Adveq

Redalpine Venture Partners
加载更多

ImmunOs Therapeutics

基本信息

投融资

相关投融资企业